{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:29:02Z","timestamp":1771921742801,"version":"3.50.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer has been associated with prolonged acute obstructive and irritative lower urinary tract symptoms (LUTS). Prophylactic alpha-adrenergic antagonists have been used therapeutically to prevent obstructive symptoms in patients undergoing prostate SBRT, however irritative symptoms may be better addressed with beta 3-adrenergic receptor agonists, which are shown to be safe and effective in men with overactive bladder (OAB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study retrospectively examines the pattern of bothersome urinary frequency associated with SBRT to determine which patients would have potentially benefitted from prophylactic beta 3-adrenergic receptor agonist.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with clinically localized prostate cancer who underwent prostate SBRT (n=1676) were followed for 3 months post-treatment to evaluate for bothersome urinary frequency, which was assessed by question 4E on the EPIC-26. Answers to question 4E and tamsulosin usage were recorded at regular follow-ups to assess, and demographic factors as well as baseline prostate volume, alpha-adrenergic antagonist usage and IPSS score severity were used as modifiers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Using the IPSS questionnaire to determine baseline LUTS, most patients reported moderate urinary symptoms (53%), followed by mild (34%) and severe (13%). Patients endorsed increased irritative LUTS at 1-month post-SBRT, with similar rates of frequency at 3 months compared to baseline. Patients with moderate and severe urinary symptoms per the baseline IPSS were more likely to endorse bothersome urinary frequency at one month post SBRT (EPIC-26 Q4E; OR 2.58 and 10.2 respectively) compared to those with mild symptoms. No significant differences were found in urinary frequency between patients who used and did not use an alpha antagonist at baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Bothersome post-SBRT urinary frequency persists 1-month post-SBRT. Baseline LUTS predicts bothersome post-treatment urinary frequency. Prophylactic alpha-adrenergic antagonists do not protect against bothersome acute urinary frequency. This paper makes the case that urinary frequency may be better addressed with a prophylactic beta-3 agonist, like vibegron, which is designed to treat storage-related LUTS concerns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1642614","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:19:08Z","timestamp":1768454348000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Persistent bothersome urinary frequency following stereotactic body radiation therapy for clinically localized prostate cancer: rationale for prophylactic \u03b23-agonist in men with elevated baseline international prostate symptom scores"],"prefix":"10.3389","volume":"15","author":[{"given":"Jennifer","family":"Zack","sequence":"first","affiliation":[{"name":"School of Medicine, Georgetown University","place":["Washington, DC, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Ji","family":"Koh","sequence":"additional","affiliation":[{"name":"School of Medicine, Georgetown University","place":["Washington, DC, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Lindbloom","sequence":"additional","affiliation":[{"name":"School of Medicine, Georgetown University","place":["Washington, DC, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"School of Medicine, Georgetown University","place":["Washington, DC, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Gaudian","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Georgetown University Hospital","place":["Washington, DC, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Zwart","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Georgetown University Hospital","place":["Washington, DC, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malika","family":"Danner","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Georgetown University Hospital","place":["Washington, DC, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Kumar","sequence":"additional","affiliation":[{"name":"Biotechnology Research Institute, North Carolina Central University","place":["Durham, NC, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simeng","family":"Suy","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of South Florida (USF) Health Morsani College of Medicine","place":["Tampa, FL, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Hankins","sequence":"additional","affiliation":[{"name":"Department of Urology, Georgetown University Hospital","place":["Washington, DC, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Collins","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of South Florida (USF) Health Morsani College of Medicine","place":["Tampa, FL, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1748-717X-8-58","article-title":"Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience","volume":"8","author":"Chen","year":"2013","journal-title":"Radiat Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Net Open"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2015.11.043","article-title":"Assessment and management of male lower urinary tract symptoms (LUTS)","volume":"25","author":"Abdelmoteleb","year":"2016","journal-title":"Int J Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00227","article-title":"Utilization of patient-reported outcomes to guide symptom management during stereotactic body radiation therapy for clinically localized prostate cancer","volume":"7","author":"Danner","year":"2017","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2016.00122","article-title":"Acute urinary morbidity following stereotactic body radiation therapy for prostate cancer with prophylactic alpha-adrenergic antagonist and urethral dose reduction","volume":"6","author":"Repka","year":"2016","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(99)00246-1","article-title":"Tamsulosin palliates radiation-induced urethritis in patients with prostate cancer: results of a pilot study","volume":"45","author":"Prosnitz","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01840-X","article-title":"Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy","volume":"60","author":"Merrick","year":"2002","journal-title":"Urology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0090-4295(02)01784-3","article-title":"Definition and epidemiology of overactive bladder","volume":"60","author":"Wein","year":"2002","journal-title":"Urology"},{"key":"B10","article-title":"The prevalence of overactive bladder","volume":"6","author":"Milsom","year":"2000","journal-title":"Am J Manag Care"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2147\/RRU.S102441","article-title":"Review of the epidemiology of overactive bladder","volume":"8","author":"Eapen","year":"2016","journal-title":"Res Rep Urol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.10.046","article-title":"Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review","volume":"191","author":"Veenboer","year":"2014","journal-title":"J Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001440","article-title":"Persistence and adherence of anticholinergics and beta-3 agonist for the treatment of overactive bladder: systematic review and meta-analysis, and network meta-analysis","volume":"205","author":"Song","year":"2021","journal-title":"J Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2021.08.011","article-title":"Choosing the most efficacious and safe oral treatment for idiopathic overactive bladder: A systematic review and network meta-analysis","volume":"8","author":"Mostafaei","year":"2022","journal-title":"Eur Urol Focus"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S148","DOI":"10.5489\/cuaj.2310","article-title":"Update on medical therapy for male LUTS","volume":"8","author":"Radomski","year":"2014","journal-title":"Can Urologic Assoc J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.05.062","article-title":"Urodynamics and safety of the \u03b23-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction","volume":"190","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003999","article-title":"Efficacy and safety of vibegron for persistent symptoms of overactive bladder in men being pharmacologically treated for benign prostatic hyperplasia: results from the phase 3 randomized controlled COURAGE trial","volume":"212","author":"Staskin","year":"2024","journal-title":"J Urol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S0090-4295(00)00858-X","article-title":"Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer","volume":"56","author":"Wei","year":"2000","journal-title":"Urology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/2042098616659412","article-title":"Mirabegron in overactive bladder patients: efficacy review and update on drug safety","volume":"7","author":"Warren","year":"2016","journal-title":"Ther Adv Drug Safe"},{"key":"B21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.urology.2021.12.018","article-title":"Mirabegron reduces urinary frequency and improves overactive bladder symptoms at 3 months after 125I-brachytherapy for prostate cancer: an open-labeled, randomized, non\u2013placebo-controlled study","volume":"161","author":"Nakai","year":"2022","journal-title":"Urology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ccl.2024.09.003","article-title":"Cardiovascular risk in prostate cancer","volume":"43","author":"Leong","year":"2025","journal-title":"Cardiol Clin"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1642614\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T06:54:55Z","timestamp":1771916095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1642614\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":22,"alternative-id":["10.3389\/fonc.2025.1642614"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1642614","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"article-number":"1642614"}}